NCT04730804View on ClinicalTrials.gov

A Study of ALXN1830 in Healthy Adult Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

December 14, 2021

Study Completion Date

January 4, 2022

Conditions
Healthy
Interventions
DRUG

ALXN1830

ALXN1830 will be administered as SC infusion(s).

DRUG

Placebo

Placebo will be administered as SC infusion(s).

Trial Locations (2)

1010

Research Site, Grafton

Unknown

Clinical Trial Site, Auckland

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY